This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Visser, L H Articles by Lenderink, A W Search for Related Content PubMed PubMed Citation Articles by Visser, L H Articles by Lenderink, A W Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METHYLPREDNISOLONE Social Bookmarking                   What's this?

A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS

Department of Neurology, St. Elisabeth Hospital, Tilburg, The Netherlands, l.visser{at}elisabeth.nl

R Beekman

Department of Neurology, St. Elisabeth Hospital, Tilburg, The Netherlands

C C Tijssen

Department of Neurology, St. Elisabeth Hospital, Tilburg, The Netherlands

B MJ Uitdehaag

Department of Clinical Epidemiology and Biostatistics, VU Medical Centre, Amsterdam

M L Lee

Department of Biostatistics, University of California, Los Angeles, California, USA

K LL Movig

Department of Pharmacy, St. Elisabeth Hospital, Tilburg, The Netherlands

A W Lenderink

Department of Pharmacy, St. Elisabeth Hospital, Tilburg, The Netherlands

Background: Some patients with multiple sclerosis (MS) do not show a clear improvement of acute relapses after treatment with intravenous methylprednisolone (IVMP). We compared the efficacy of the combination of intravenous immunoglobulins (IVIg) and IVMP with the standard treatment of IVMP alone in promoting recovery from moderate to severe acute relapses in MS. Methods: Patients with clinically definite MS having a relapse with at least a one point increase in Kurtzke’s expanded disability status scale (EDSS) in comparison to the preattack EDSS were randomized to IVMP-IVIg or IVMP-placebo treatment. The primary outcome criterion was the EDSS grade at four weeks. A preplanned interim analysis was performed after inclusion of 19 consecutive MS patients to evaluate the sample size necessary for a larger trial. Findings: Both groups had improved one point on the EDSS four weeks after start of treatment (P =0.81) and one of the stopping rules of the interim analysis was fulfilled. There were also no differences in secondary outcomes: EDSS at eight and 12 weeks, time to improve]-1 EDSS points, difference in Scripps score and ambulation index. Five patients in the IVMP-IVIg group and two in the IVMP group had a new relapse in the six month follow-up. Interpretation: O ur study could not show superiority of IVMP-IVIg in the treatment of moderate to severe acute relapses in MS.

Key Words: combination therapy • intravenous immune globulins • intravenous methylprednisolone • multiple sclerosis • relapses • treatment

Multiple Sclerosis, Vol. 10, No. 1, 89-91 (2004)
DOI: 10.1191/1352458504ms978sr


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Stangel Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 115 - 124. [Abstract] [PDF]

				D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group Treatment of pediatric multiple sclerosis and variants Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65. [Abstract] [Full Text] [PDF]

				E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]

				P. Soelberg Sorensen, J. Haas, F. Sellebjerg, T. Olsson, M. Ravnborg, and the TARIMS Study Group IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS Neurology, December 14, 2004; 63(11): 2028 - 2033. [Abstract] [Full Text] [PDF]